AmeriCann to Present at The MicroCap Conference in New York
City
Presentation Scheduled for Tuesday, April 4 at 9:30am EST
DENVER, CO -- March 27, 2017 -- InvestorsHub NewsWire --
AmeriCann, Inc. (OTCQX:
ACAN), an Ag-Tech company that is developing sustainable,
state-of-the-art medical cannabis cultivation properties, announced
today that Tim Keogh, Chief Executive Officer, will present at The
MicroCap Conference in New York City on April 4, 2017.
The MicroCap Conference is an exclusive event for investors who
specialize in MicroCap Companies to conduct one-on-one meetings
with AmeriCann and other participating companies as well view as
formal presentations. The conference will be held at The JW
Marriott Essex House, 160 Central Park South, New York, NY 10019 at
9:30am ET on Tuesday, April 4, 2017 and.
AmeriCann is developing a 53-acre property in Massachusetts
(acquired from Boston Beer Company (SAM-NYSE) for $4,475,000 in
cash), as the Massachusetts Medical Cannabis Center (the MMCC). The
MMCC is approved for 1 million square feet and is expected to be
one of the largest and most technologically advanced cannabis
cultivation facilities in the nation.
The regulated cannabis industry is one of the fastest growing
industries in the country. The respected Wall Street firm of Cowen
& Co recently released a research report projecting dramatic
growth for the industry from the current $7 billion nationally to
over $50 billion in ten years.
In November of 2016, Massachusetts, California, Maine, and
Nevada voted to legalize recreational marijuana while Arkansas and
North Dakota approved medical cannabis initiatives. Florida
voters approved medical marijuana in a landslide with over 71% of
the vote. With these election results, over 60% of the US
Population now live in states where medical cannabis is now
legal.
About The MicroCap Conference
The MicroCap Conference is an exclusive event for investors who
specialize in MicroCap Companies. It's an opportunity to be
introduced to and speak with management at some of the most
attractive small companies, to learn from our various expert
panels, and to network with buyside analysts and other micro cap
investors.
For those interested in attending, please contact Fred Rockwell
at fred@microcapconf.com or visit www.microcapconf.com/conferences/new-york-2017/ for
more information.
About AmeriCann
AmeriCann (OTCQX:
ACAN) is a publicly traded Ag-Tech company that is developing
and sustainable, state-of-the-art medical cannabis cultivation
properties. The Company has over 1,000,000 square feet of
facilities in the planning and design stages of development. The
Company has designed a proprietary line of cannabis infused
products which will be branded and licensed to companies in
regulated markets.
AmeriCann, Inc. is a Certified B
Corp, an acknowledgment of the companys commitment to social
and environmental ethics, transparency and accountability. AmeriCann became the first public
cannabis company to earn this respected accreditation. More
information about the Company is available at: www.americann.co or follow AmeriCann on Twitter @ACANinfo
About Massachusetts Medical Cannabis Center
The Massachusetts Medical Cannabis Center is approved for
nearly 1,000,000 square feet of medical cannabis
cultivation and processing in Freetown, Massachusetts. The
state-of-the-art, sustainable, greenhouse project will consist of
multiple planned phases for tenants in the Massachusetts medical
marijuana market. AmeriCanns Cannopy System uniquely combines
expertise from traditional horticulture, lean manufacturing,
regulatory compliance and cannabis cultivation to create superior
facilities and procedures.
The first phase of the project consists of 130,000 sq. ft. of
cultivation and processing infrastructure. AmeriCann can expand the
first phase to approximately 600,000 sq. ft., based on patient
demand.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended (the Exchange Act) (which Sections were adopted as part of
the Private Securities Litigation Reform Act of 1995). Statements
preceded by, followed by or that otherwise include the words
believe, anticipate, estimate, expect, intend, plan, project,
prospects, outlook, and similar words or expressions, or future or
conditional verbs such as will, should, would, may, and could are
generally forward-looking in nature and not historical facts. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the Company's
actual results, performance or achievements to be materially
different from any anticipated results, performance or
achievements. The Company disclaims any intention to, and
undertakes no obligation to, revise any forward-looking statements,
whether as a result of new information, a future event, or
otherwise. For additional uncertainties that could impact the
Company's forward-looking statements, please see the Companys
Annual Report on Form 10-K for the year ended September 30, 2016,
which the Company has filed with the SEC and which may be viewed at
http://www.sec.gov.
Contact Information:
Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co
@ACANinfo on Twitter
Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878